LEV PHARMACEUTICALS INITIATES PROPHYLAXIS TREATMENT IN TRIAL FOR HEREDITARY ANGIOEDEMA

LEV PHARMACEUTICALS INITIATES PROPHYLAXIS TREATMENT IN TRIAL FOR HEREDITARY ANGIOEDEMA

Lev Pharmaceuticals has announced the initiation of prophylaxis treatment as part of its ongoing Phase III clinical trial for the company's lead product candidate, C1-esterase inhibitor (C1-INH), for hereditary angioedema (HAE).

The multicenter, placebo-controlled, double-blind study is designed to examine the efficacy and safety of C1-INH in preventing the onset of HAE attacks. A second part of the study is specifically examining the ability of C1-INH to prevent such inflammatory attacks.